I. AMENDMENT

In the Claims:

The following listing of claims will replace all prior versions and listings of the claims in the application:

Listing of the Claims:

- 1-9. (Canceled)
- (Previously Presented) The method of claim 17, wherein said mRNA is amplified by an RNA polymerase reaction.
- (Previously Presented) The method of claim 17, wherein said mRNA is amplified by reverse transcriptase polymerase chain reaction or the ligase chain reaction.
- (Previously Presented) The method of claim 17, wherein said detecting is by RNA fingerprinting, branched DNA or a nuclease protection assay.

13-14. (Canceled)

- (Previously Presented) The method of claim 17, wherein the metastatic cancer is metastatic prostate cancer.
- (Previously Presented) The method of claim 17, wherein the metastatic cancer is
- 17. (Currently Amended) A method of detecting metastatic cancer, comprising the steps of:
 - detecting the quantity of a disease marker mRNA expressed in human peripheral blood; and

 (b) comparing the quantity of said marker to the quantity expressed in peripheral blood of a normal individual;

wherein said mRNA comprises ene or more of the sequences or the complements of the sequences disclosed herein as SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:29, SEQ ID NO:34, SEQ ID NO:48 or SEQ ID NO:49 and wherein a difference in quantity of expression is indicative of metastatic cancer.

- 18. (Canceled)
- 19. (Previously Presented) The method of claim 17, further comprising the steps of
 - a) providing primers that selectively amplify said metastatic cancer marker;
 - amplifying said nucleic acid with said primers to form nucleic acid amplification products;
 - c) detecting said nucleic acid amplification products; and
 - measuring the amount of said nucleic acid amplification products formed.
- (Currently Amended) The method of claim 19 in which said primers are selected to specifically amplify a nucleic acid having a sequence comprising SEQ-ID-NO:1, SEQ-ID-NO:2, SEQ-ID-NO:3, SEQ-ID-NO:29, SEQ-ID-NO:34, SEQ-ID-NO:48-or-SEQ-ID-NO:49.
- 21-73. (Canceled)